Skip to main content
. Author manuscript; available in PMC: 2022 Feb 24.
Published in final edited form as: ACS Appl Mater Interfaces. 2021 Feb 12;13(7):7913–7923. doi: 10.1021/acsami.0c19955

Figure 1.

Figure 1.

Schematic showing the modular design of a PLGA-based aAPC for melanoma immunotherapy. A PLGA/PBAE blend is explored as a novel core material for the aAPC to enhance presentation of surface-conjugated MHC Ig loaded with melanoma antigenic peptides (Signal 1) and Signal 2 molecules.